2026-08-20 · oral GLP-1, Rybelsus, orforglipron, VK2735, amycretin, oral weight loss pill, next-generation obesity drug
Written by Nora Kim
Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.
17 min read
Medically reviewed on Aug 20, 2026
Oral GLP-1 Weight Loss Medications Compared: Rybelsus, Orforglipron, VK2735, and Oral Amycretin (2026)
Quick answer: Four oral GLP-1-class weight-loss medications matter in 2026 — Rybelsus (approved 2019 for T2D, ~4 to 4.5 percent weight loss at 14 mg, off-label for weight loss), orforglipron (Lilly, ATTAIN-1 Phase 3 ~12.4 percent at 72 weeks, FDA action expected 2026–2027), VK2735 oral (Viking, small-molecule GLP-1/GIP dual, Phase 1 tablet), and oral amycretin (Novo, Phase 1b, ~13.1 percent at 12 weeks at 50 mg). Only Rybelsus is on US pharmacy shelves. The single event that changes the 2026–2027 practical landscape is the FDA orforglipron decision.
Quick stats
- Rybelsus 14 mg — ~4 to 4.5% at 26–52 wk (Aroda 2019 PIONEER-1). SNAC + empty stomach + 4 oz water + 30-min fast.
- Orforglipron 36 mg — ~12.4% at 72 wk (ATTAIN-1 topline). Small molecule, no fasting rule.
- VK2735 oral — Phase 1 SAD/MAD in progress; SC form ~14.7% at 13 wk (VENTURE-1). Small molecule, GLP-1/GIP dual.
- Oral amycretin 50 mg — ~13.1% at 12 wk (Rosenstock 2025 Lancet). SNAC + amylin/GLP-1 co-agonist.
For the broader landscape covering injectables, see GLP-1 weight loss medications compared, and for the deeper pipeline (retatrutide, MariTide, CagriSema, mazdutide), see next-generation weight loss drugs.
What “oral GLP-1” actually means in 2026
“Oral GLP-1” is not a single class in 2026 — it is three distinct engineering paths for delivering a GLP-1 receptor agonist through the gut, and understanding which path a given drug uses explains almost everything about how it is dosed and how much it can lose.
- Path 1 — Peptide + SNAC absorption enhancer. Rybelsus is a peptide (semaglutide, the same molecule as Ozempic and Wegovy) packaged with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC transiently opens tight junctions in the gastric mucosa so the peptide can cross before digestion destroys it. The trade-off is a strict administration protocol: empty stomach, no more than 4 oz of plain water, and a 30-minute wait before food, drink, or other medications. Bioavailability is roughly 1 percent under ideal conditions and drops further when the protocol is broken (Overgaard 2019, Clinical Pharmacokinetics). Oral amycretin uses the same SNAC platform.
- Path 2 — Small-molecule non-peptide agonist. Orforglipron and VK2735 oral are chemical entities engineered to survive gastric pH and cross the mucosa without an absorption enhancer. No SNAC, no fasting rule, no water restriction, room-temperature stable. They can be taken with or without food, at any time of day. The design template was demonstrated by Pratt 2023 on Lilly’s biased-agonism preclinical program.
- Path 3 — SNAC + non-GLP-1-only mechanism. Oral amycretin is a peptide co-agonist that activates both the GLP-1 receptor and the amylin receptor from a single molecule, and it uses the SNAC platform for absorption. It is a hybrid — SNAC-based delivery like Rybelsus, but engineered around two receptors instead of one.
The plain-English framing: oral GLP-1s are not one class — they are three distinct engineering paths, and the path decides the fasting rule, the water restriction, and (largely) the achievable weight-loss magnitude.
The four drugs in one paragraph each
Rybelsus (oral semaglutide, Novo Nordisk, FDA-approved 2019 for T2D, off-label for weight loss). The only oral GLP-1 on US pharmacy shelves. Peptide semaglutide packaged with SNAC; requires empty stomach, ≤4 oz of plain water, and a 30-minute fasting window every morning. The PIONEER-1 Phase 3 trial (Aroda 2019, Diabetes Care) reported roughly 4 to 4.5 percent placebo-adjusted weight loss over 26 weeks at the 14 mg maintenance dose. In 2025 the FDA added a cardiovascular-risk-reduction indication in T2D with established atherosclerotic disease (McGuire 2025 SOUL, NEJM). A higher-dose (50 mg) oral semaglutide formulation for chronic weight management is under FDA review based on the OASIS program, with reported weight loss around 15 percent at 68 weeks — but the 50 mg formulation is not the 3/7/14 mg Rybelsus tablet sold today.
Orforglipron (Eli Lilly, Phase 3 ATTAIN, FDA action expected 2026–2027). A small-molecule non-peptide GLP-1 receptor agonist — no SNAC, no fasting rule, can be taken with or without food. The ATTAIN-1 Phase 3 obesity topline reported roughly 12.4 percent placebo-subtracted weight loss at 72 weeks on the 36 mg dose, with roughly 60 percent of patients hitting 15 percent or more. The ACHIEVE-1 Phase 3 T2D readout (April 2025) reported HbA1c reductions of 1.3 to 1.6 percent and ~7.9 percent weight loss at 36 mg over 40 weeks. Lilly filed the NDA in Q4 2025; realistic FDA action window is Q3–Q4 2026 for T2D and 2027 for obesity. Practical shelf access for weight loss is late 2027 or 2028 after payer ramp.
VK2735 oral (Viking Therapeutics, Phase 1 tablet program). A small-molecule GLP-1 / GIP dual agonist developed in parallel as a weekly subcutaneous injection and a daily oral tablet. The SC form’s VENTURE-1 Phase 2 topline (Viking, March 2024) reported roughly 14.7 percent placebo-adjusted weight loss at just 13 weeks at the 5 mg SC dose — the largest short-window Phase 2 obesity signal reported to date. The oral tablet is in Phase 1 single-ascending-dose and multiple-ascending-dose work (VENTURE-2 program); topline for the oral formulation is expected in the second half of 2026. Realistic FDA availability is 2028–2029 for the SC form and 2030 or later for the oral tablet. If VK2735 oral succeeds, it would be the first daily oral dual-receptor GLP-1/GIP drug.
Oral amycretin (Novo Nordisk, Phase 1b). A single-molecule amylin + GLP-1 co-agonist on Novo’s SNAC oral platform — the same absorption technology as Rybelsus. The Rosenstock 2025 Phase 1b oral trial (Lancet) enrolled 144 adults with obesity and reported roughly 13.1 percent mean weight loss at the 50 mg dose over just 12 weeks — the first oral obesity drug candidate ever to deliver double-digit weight loss in a short window. Oral amycretin Phase 2 initiated Q1 2026 with a ~500-patient 52-week readout expected late 2027; Phase 3 filings are anticipated in 2028, putting realistic US availability no sooner than 2030.
Comparison table — the reader’s primary reference
| Drug | Molecule class | Route + fasting rule | Phase / status | Peak weight loss (study) | Typical adult dose | Earliest realistic FDA availability (obesity) |
|---|---|---|---|---|---|---|
| Rybelsus (oral semaglutide) | Peptide + SNAC | Daily oral, empty stomach + ≤4 oz water + 30-min fast | FDA-approved 2019 for T2D (off-label for weight loss) | ~4–4.5% at 26 wk (Aroda 2019 PIONEER-1) | 3 mg → 7 mg → 14 mg once daily | On shelves; 50 mg oral obesity formulation under FDA review |
| Orforglipron (LY3502970) | Small-molecule non-peptide GLP-1 | Daily oral, any time, with or without food | Phase 3 complete; NDA filed Q4 2025 | ~12.4% at 72 wk (ATTAIN-1 topline) | 36 mg once daily (top dose) | 2026–2027 (T2D likely first); 2027–2028 for weight-loss shelf |
| VK2735 oral | Small-molecule non-peptide GLP-1 / GIP dual | Daily oral, no fasting rule expected | Phase 1 SAD/MAD (oral); Phase 2/3 (SC) | Oral not yet reported; SC ~14.7% at 13 wk (VENTURE-1 5 mg) | Not yet defined | 2030 or later (oral); 2028–2029 (SC) |
| Oral amycretin | Peptide amylin + GLP-1 co-agonist + SNAC | Daily oral, empty stomach + small-sip water + 30-min fast | Phase 1b complete; Phase 2 initiated Q1 2026 | ~13.1% at 12 wk (Rosenstock 2025 Lancet, 50 mg) | 50 mg once daily (Phase 1b top dose) | 2030 or later |
Peak weight-loss numbers are drawn from the highest-dose arm of the primary published trial for each drug and are not head-to-head comparable — trial durations, populations, and placebo-response baselines differ.
Why oral matters — the adherence and access story
The oral shelf is not “better efficacy per mg” than the injectable shelf. On weight-loss magnitude alone, injectable Wegovy (~14.9 percent at 68 weeks in STEP-1, Wilding 2021, NEJM) and injectable Zepbound (~20.9 percent at 72 weeks in SURMOUNT-1) outperform the current best oral (Rybelsus, ~4 to 4.5 percent) by a wide margin. The case for oral is better real-world adherence and wider access, not more weight loss per dose.
The adherence problem for injectable GLP-1s is real. A Wilding 2025 STEP-1 adherence follow-up reported roughly 40 percent one-year discontinuation on injectable semaglutide in real-world use — well above the ~15 percent seen in the tightly controlled STEP-1 randomized trial. Real-world discontinuation on tirzepatide runs in a similar 30 to 45 percent range at one year. The concrete practical advantages of an oral drug speak directly to that gap:
- No needle anxiety. Roughly 10 to 20 percent of adults report a clinically meaningful degree of needle phobia (Ismail 2020), and even mild needle aversion drives injection-day skipping in weekly-injection regimens.
- No injection-site reactions. Weekly SC injections produce local nodules, bruising, and injection-site itching in a meaningful minority — the amylin arm of amycretin SC and cagrisema produced roughly 15 percent injection-site nodules at high doses.
- No cold-chain storage. Rybelsus is room-temperature stable; small-molecule non-peptide orals (orforglipron, VK2735) are even more stable. Injectable GLP-1 pens require refrigeration, which is a real constraint for travel, dorm living, and low-resource households.
- Easier travel and prescribing. No sharps container, no pen assembly, no dose-loading step, easier to prescribe to patients who cannot manage self-injection (older adults with tremor, patients with severe arthritis).
- Broader class-wide access. Small-molecule non-peptide oral tablets are ~10× cheaper to manufacture than injectable peptides (analyst estimates on orforglipron cost of goods), which should give payers more room to negotiate down list price and give manufacturers room to offer direct-cash programs at the $300–$500 monthly band.
The practical case for oral is that a drug that fits the patient’s actual life gets taken. A tablet with 80 percent adherence outperforms an injection with 55 percent adherence, even when the injection is stronger per dose.
The SNAC-vs-small-molecule engineering split
The two dominant oral GLP-1 engineering paths in 2026 look different from the outside — one requires a strict fasting protocol and one does not — because they solve the same delivery problem in fundamentally different ways.
Path A — SNAC absorption enhancer. Semaglutide and amycretin are peptides — long chains of amino acids that are destroyed by gastric acid and gut proteases within minutes of ingestion. To deliver a peptide orally, Novo Nordisk engineered a co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that transiently opens tight junctions in the gastric mucosa and creates a local environment (transient pH shift, temporarily relaxed epithelial barrier) that allows the intact peptide to cross into circulation before it is digested. The mechanism was characterized in Buckley 2018 (Science Translational Medicine). Bioavailability under ideal conditions is roughly 1 percent — low, but sufficient because the peptide is highly potent. The trade-off is that SNAC’s local environment is fragile: food, more than 4 oz of any beverage, coffee, juice, or another medication in the stomach at the same time will collapse the local pH and drop absorption toward zero. The empty-stomach + 4 oz plain-water + 30-minute fast protocol is not an inconvenience layered onto the drug — it is the SNAC platform working.
Path B — Small-molecule non-peptide agonist. Orforglipron and VK2735 oral do not use peptides at all. They are chemical entities — conventional small-molecule drugs designed from scratch to bind the GLP-1 receptor (and, for VK2735, also the GIP receptor) while surviving gastric pH and crossing the intestinal mucosa without an absorption enhancer. The design template combined structure-based drug discovery with biased agonism: Pratt 2023 describes Lilly’s approach on orforglipron, engineering a molecule that pushes GLP-1 receptor signaling toward the cAMP-mediated satiety and insulin pathways while sparing the beta-arrestin arm that drives tachyphylaxis. Because the drug crosses the gut wall by ordinary passive and active transport rather than through transiently opened tight junctions, food and beverages have no meaningful effect on absorption — no fasting rule, no water restriction, no timing constraint. Room-temperature stable, no refrigeration.
The practical implication: the fasting rule is a SNAC-platform artifact, not a class-wide GLP-1 property. Small-molecule non-peptide oral GLP-1 agonists (orforglipron, VK2735 oral) do not have a fasting rule and will not gain one.
Efficacy honest read
Ranking the four drugs by peak weight-loss magnitude reported so far is possible but the ranking is directional, not definitive — every side-by-side is between separate studies with different durations, populations, and placebo-response baselines. No head-to-head oral-vs-oral GLP-1 trial has been published.
| Drug | Peak weight loss | Trial duration | Trial phase | Head-to-head vs Wegovy? |
|---|---|---|---|---|
| Oral amycretin 50 mg | ~13.1% | 12 weeks | Phase 1b (n=144, Rosenstock 2025) | No |
| Orforglipron 36 mg | ~12.4% | 72 weeks | Phase 3 (ATTAIN-1 topline) | No |
| VK2735 oral | Not yet reported | Phase 1 in progress | Phase 1 SAD/MAD | No |
| Rybelsus 14 mg | ~4–4.5% | 26 weeks | Phase 3 (Aroda 2019 PIONEER-1) | Wegovy 2.4 mg is stronger (~14.9% STEP-1) |
Two important caveats on the ranking:
- Trial duration is not comparable. Amycretin’s 13.1 percent is at 12 weeks and has not plateaued; the eventual 52-week Phase 2 number will very likely be higher. Orforglipron’s 12.4 percent is at 72 weeks — a longer and more mature curve. Rybelsus’s 4 to 4.5 percent is at 26 weeks in a T2D population, which typically loses less weight per drug than an obesity-only population. Comparing peak numbers across those durations overstates the certainty.
- Rybelsus’s low magnitude is partly a dosing artifact. The 14 mg maximum was set for the T2D indication where diminishing returns on glycemic effect made higher doses unnecessary. Novo’s OASIS program tested a 50 mg oral semaglutide dose specifically for chronic weight management and reported roughly 15 percent weight loss at 68 weeks in OASIS-1 (Knop 2023, Lancet), matching injectable Wegovy 2.4 mg. If the FDA approves the OASIS 50 mg tablet for weight loss (filing under review in 2026), the “oral semaglutide is weak” framing becomes obsolete overnight — the 3/7/14 mg Rybelsus tablets sold today are simply not the weight-loss dose.
The single honest one-line summary: at 2026 doses, oral amycretin > orforglipron > Rybelsus for magnitude, but only orforglipron and Rybelsus are anywhere close to the pharmacy shelf.
Tolerability comparison
GI-dominant tolerability is the class signature and applies to all four drugs. The distinguishing question is not “is there nausea” but “how much, when, and does the delivery route change it.”
- Rybelsus 14 mg — Nausea 15–20 percent, vomiting 5–10 percent, diarrhea 8–12 percent in PIONEER-1 (Aroda 2019). The SNAC platform produces a specific pattern: more early nausea in the first 30 to 60 minutes after each dose than injectable semaglutide, driven by peak-and-trough absorption kinetics. Discontinuation for GI intolerance was ~7 to 10 percent at 14 mg.
- Orforglipron 36 mg — Nausea 15–25 percent, vomiting 5–15 percent, diarrhea 10–15 percent (Wharton 2023 Phase 2 and ACHIEVE-1 Phase 3 topline). Small-molecule non-peptide delivery gives a smoother pharmacokinetic profile than SNAC-based orals, and reported tolerability at 36 mg is broadly similar to injectable Wegovy 2.4 mg. Discontinuation for GI intolerance was ~5 to 10 percent at 36 mg.
- VK2735 oral — Tolerability rates not yet reported. Phase 1 SAD/MAD data is under corporate wraps; the SC form’s VENTURE-1 topline (Viking, March 2024) reported nausea in roughly 25 to 40 percent at high doses over 13 weeks — a class-typical GLP-1/GIP dual pattern.
- Oral amycretin 50 mg — Nausea 25–35 percent at the top dose, vomiting 10–20 percent, diarrhea 5–15 percent (Rosenstock 2025 Lancet). Two contributions to the higher rate: the SNAC platform’s early-nausea signal (same as Rybelsus) and the amylin arm’s additional GI slowdown (long-acting amylin analogs consistently produce more nausea than GLP-1 alone at matched exposure). Titration will help; the Phase 1b did not use a full stepwise titration.
The takeaway: SNAC-based orals (Rybelsus, oral amycretin) produce more early first-hour nausea than small-molecule non-peptide orals (orforglipron, VK2735 oral), which is a real quality-of-life difference for patients weighing “how the drug feels” against “how much it loses.”
The 2026 US-shelf reality
This is the explicit does-not-do section. In August 2026, the practical US oral-GLP-1 shelf is very small.
- Rybelsus is on shelves — but only for T2D. FDA-approved 2019 for type 2 diabetes and, since January 2025, for cardiovascular risk reduction in T2D with established atherosclerotic disease. Off-label use for weight loss without a T2D diagnosis is not covered by commercial insurance, Medicare Part D, or Medicaid in almost any case, and cash price is roughly $1,000 per month. The higher-dose 50 mg oral semaglutide obesity formulation (OASIS program) is under FDA review; if approved, that specific product — not the 3/7/14 mg Rybelsus tablet — will be the on-label oral weight-loss option.
- Orforglipron is not yet approved. NDA filed Q4 2025; realistic FDA action window is Q3–Q4 2026 for T2D and 2027 for chronic weight management, with practical payer-covered shelf access in the 2027–2028 window.
- VK2735 oral is Phase 1. Earliest realistic FDA approval for the oral formulation is 2030 or later; the SC form is closer, at 2028–2029.
- Oral amycretin is Phase 1b. Phase 2 initiated Q1 2026 with a ~500-patient 52-week readout expected late 2027. Earliest realistic FDA approval is 2030 or later.
Do not respond to any grey-market vendor selling “oral tirzepatide,” “oral orforglipron,” “compounded oral GLP-1,” or generic “oral GLP-1 peptide” in 2026. The reasons are specific and mechanical, not a general caution:
- Tirzepatide has never been an oral drug. It is a peptide and no oral formulation has been developed by Lilly. Any product sold as “oral tirzepatide” is not the drug from the trials.
- Orforglipron is a proprietary Lilly small molecule and is not compoundable by any FDA-recognized pathway. The molecule was never on the FDA drug-shortage list; no compounding pharmacy has legitimate access to it.
- Peptide semaglutide sold as “oral” without the SNAC formulation is not the drug from Rybelsus. The SNAC platform is what makes oral semaglutide work; a peptide without SNAC will not be meaningfully absorbed.
- Amycretin and VK2735 are proprietary molecules never on the FDA shortage list and not compoundable.
How to think about the choice as a patient in 2026
Three concrete decision-frames cover most patient situations.
(a) You are already on Rybelsus for T2D and would also like weight loss. Expect roughly 4 to 6 percent weight loss at the 14 mg maintenance dose over 6 months on top of glycemic effect. That is modest. If weight loss is a primary goal and your BMI meets criteria (BMI ≥30 or BMI ≥27 with a weight-related condition), talk to your prescriber about switching or adding injectable Wegovy 2.4 mg SC weekly — same molecule (semaglutide), much stronger weight-loss signal (~14.9 percent in STEP-1). If instead the question is whether to stay oral or move to same-molecule injectable Ozempic for T2D glycemic and modest additional weight-loss benefit, the direct route-vs-route walkthrough — PIONEER 4 head-to-head data, the current 2026 dose-ceiling gap, and where the fasting-water rule flips the decision — is in Rybelsus vs Ozempic. The T2D indication may complicate coverage; see prescription weight loss medications for the payer landscape and GLP-1 cost and insurance for a 2026 pricing table.
(b) You are waiting for orforglipron to launch. Realistic timeline is 12 to 24 months from FDA approval to practical shelf access after prior-authorization ramp — the shelf date is late 2027 at earliest, 2028 more realistically. Do not delay starting Wegovy or Zepbound today if either is available to you and clinically appropriate. Starting now and evaluating an orforglipron switch after approval is the higher-evidence path. A year of measurable weight loss and cardiometabolic improvement now is worth more than an untried theoretical better drug in 12 to 24 months.
(c) You are waiting for VK2735 oral or oral amycretin. Realistic timeline is 4 or more years to a US pharmacy shelf. This is not a wait-and-see decision — it is a not-actionable-now decision. Start on the best-available current therapy and follow the pipeline.
Practical US-2026 read — three-sentence bottom line
For 2026 patients, the oral GLP-1 shelf is very small: Rybelsus is the only approved option and it is weight-loss modest at its current 14 mg maximum dose. The single biggest 2026–2027 event to watch is the FDA orforglipron decision — if approved, orforglipron will become the first daily oral pill with roughly Wegovy-tier weight-loss magnitude and no fasting rule, and it will meaningfully change the practical experience of GLP-1 therapy for needle-averse patients, older adults with polypharmacy issues, and everyone for whom the Rybelsus fasting protocol is not realistic. Everything past orforglipron on the oral shelf — VK2735 oral, oral amycretin — is Phase 1 or Phase 2 and years away.
References
- Aroda VR et al. PIONEER-1: Randomized clinical trial of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019;42(9):1724–1732.
- Wharton S et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. NEJM 2023;389:877–888.
- Frías JP et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study. NEJM 2023;389:958–970.
- Rosenstock J et al. Oral amycretin, a novel unimolecular GLP-1 and amylin receptor co-agonist, in adults with overweight or obesity: A phase 1b, randomised, placebo-controlled trial. Lancet 2025.
- Viking Therapeutics. VENTURE Phase 2 obesity trial topline results (VK2735 SC). Corporate press release, March 2024.
- Viking Therapeutics. VK2735 oral tablet Phase 1 program launch. Corporate update, Q4 2024.
- Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine 2018;10(467):eaar7047.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021;384:989–1002.
- Wilding JPH et al. STEP-1 adherence follow-up analysis. Novo Nordisk (most recent publication). 2025.
- Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:705–719.
- McGuire DK et al. SOUL: Cardiovascular outcomes with once-daily oral semaglutide in T2D. NEJM 2025.
- Ismail K. Needle phobia and injection avoidance in chronic disease self-management. Diabet Med 2020.
- Overgaard RV et al. Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clin Pharmacokinet 2019;58(11):1471–1487.
- Pratt E et al. Orforglipron biased-agonism preclinical program. Eli Lilly publication, 2023.